The North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) reported a 4 to 5-fold higher risk of TB reactivation in patients receiving anti-TNF therapy compared to those not receiving these medications. Here, TNF is linked to tuberculosis.